Our antibody drug conjugate development services support pharmaceutical and biotech companies in designing, optimizing, and manufacturing targeted therapeutics. We specialize in bioconjugation, linker–payload chemistry, and advanced analytical characterization to deliver consistent, high-quality ADC products.
Our bioconjugation capabilities include stochastic lysine and cysteine conjugation, as well as site-specific, enzymatic, glycoengineering, and click chemistry approaches. These methods allow precise control over conjugation, improving homogeneity, stability, and overall product performance.
We design and synthesize both cleavable and non-cleavable linkers and support a wide range of payload chemistries, including auristatins, maytansinoids, PBD dimers, and topoisomerase inhibitors. Custom payload and immune-modulating conjugates can also be developed to meet specific program requirements.
Our analytical platform supports DAR determination, conjugation-site analysis, free payload quantification, monomer purity, and serum stability. We also perform functional assays such as binding (EC50), internalization, cytotoxicity, bystander effect assessment, and PK/PD studies to guide candidate selection and mechanism validation.
We support small-scale and pilot-scale bioconjugation, along with cGMP payload-linker production for preclinical and early clinical programs. Our closed and automated processing systems integrate conjugation, purification, and tangential flow filtration (TFF) into a controlled, scalable workflow.
Our integrated CDMO approach combines antibody production, linker and payload synthesis, conjugation, analytics, and fill-finish services to streamline development timelines and reduce operational complexity. We provide full regulatory support to advance ADC candidates from discovery through clinical supply.
Our multidisciplinary teams bridge chemistry and biology to deliver robust characterization, optimized conjugation strategies, and scalable manufacturing solutions tailored to each ADC program.